7月20日，药明生物盘中上涨3.24%，报38.52港元/股，成交额1.96亿港元。
消息面上，睿远基金知名基金经理赵枫管理的睿远均衡价值三年持有混合基金近日披露二季报，药明生物新进入其前十大重仓股，持仓占比约4.34%，时隔一年重新买回该标的，机构资金入场信号提振市场信心。同时，生命科学工具和服务板块整体走强，昭衍新药涨6.06%，康龙化成涨5.78%，药明康德涨2.55%。此前7月17日该股大跌5.95%后，叠加明星基金经理加仓催化及板块回暖，短线迎来修复性反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.